TAVR and New Onset LBBB

The safety and efficacy of transcatheter aortic valve replacement (TAVR) is already established. However, it still poses a challenge for conduction disturbances, such as the need for pacemaker or new onset left bundle branch block (LBBB). The current rate for the latter ranges from approximately 11% to 19%.

TAVI y nuevo bloqueo completo de rama izquierda

In most cases, 50% of LBBB reverses in the first 24 to 48 hours after implantation, but if it is definitive, plenty of evidence suggests that it would have a deleterious effect, increasing morbidity and deteriorating ventricular function.

This study included 612 patients who received a SAPIEN 3 (S3) valve between 2015 and 2018 at the Cleveland Clinic. Among them, 70 had LBBB (11.4%).

Patient mean age was 80 years; 54% of patients were men, 89% had hypertension, 3% had diabetes, 2% required dialysis, 28% had undergone PCI, 20% had undergone CRM, 12.9% had a stroke, and 37% had COPD. Ejection fraction was preserved. 

The Society of Thoracic Surgeons mortality score was 5.7%.

Those who developed new onset LBBB had a higher QRS (97.3 ± 9.9 vs.93.5 ± 10.9 ms; p = 0.005), and greater implant depth (3.5 ± 2 vs. 2.2 ± 1.8 mm; p < 0.001), and more frequently received a 29-mm valve (41.4% vs. 22.3%; p = 0.003).

The rates of in-hospital stay were higher for those with new onset LBBB.

Read also: IN.PACT Study | Should We Start Using DCBs More Frequently in Cases of Femoropopliteal Disease?

At 30 days and at 1 year, the need for a permanent pacemaker was greater in those who experienced new onset LBBB (18.6% vs. 5.4%; p < 0.001 and 23.2% vs. 7%; p = 0.030, respectively).

There were no differences in mortality at 30 days, a year, and 3 years of follow-up.

At 12 months, hospitalizations for heart failure were higher in those with new onset LBBB (10.7% vs. 4.4%; p = 0.033).

Left ventricular ejection fraction at 30 days and at 1 year was lower in those who developed new onset LBBB (55.9 ± 11.4% vs. 9%; p = 0.026 and 12% vs. 60.1 ± 8.9%; = 0.002 respectively), regardless of whether they had an ejection fraction > or < 50%, as well as end-diastolic indexed volume (51.4 ± 18.6 vs. 46.4 ± 15.1 ml/ M2; p = 0.036) and end-systole indexed volume (23.2 ± 14.1 vs. 18.9 ± 9.7 ml/m2; p = 0.009).

Read also: Resistant Obstructive Hypertrophic Cardiomyopathy: Myomectomy or Septal Ablation?

In a multivariate regression analysis, implant depth was the only predictor of new onset LBBB.

Conclusion

New onset LBBB after TAVR with SAPIEN 3 was associated with increased need for permanent pacemaker, worse left ventricular function, larger ventricular volumes, and increased rates of hospitalization due to heart failure, with no difference in mortality.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Clinical and echocardiographic outcomes with new‐onset left bundle branch block after SAPIEN‐3 transcatheter aortic valve replacement.

Reference: Yasser M. Sammour, et al. Catheter Cardiovasc Interv. 2023;101:187–196.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...